Want to see HK:0775 full AI Analyst Report?
0775 Stock Chart & Stats
HK$0.83
>-HK$0.01(-1.22%)
At close: 4:00 PM EST
HK$0.83
>-HK$0.01(-1.22%)
Day’s Range― - ―
52-Week RangeHK$0.53 - HK$1.08
Previous CloseN/A
Volume680.00K
Average Volume (3M)5.47M
Market Cap
HK$5.14B
Enterprise ValueHK$11.92K
Total Cash (Recent Filing)HK$535.65M
Total Debt (Recent Filing)HK$6.83B
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Mar 16, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.01%
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding9,611,072,000
10 Day Avg. Volume1,467,839
30 Day Avg. Volume5,468,742
Financial Highlights & Ratios
PEG Ratio-0.90
Price to Book (P/B)2.09
Price to Sales (P/S)1.46
P/FCF Ratio-28.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Diversified Life-sciences PlatformOperating across environmental and health-related segments gives CK Life Sciences more than one route to develop revenue and apply its capabilities. In-house research, development, and commercialization can support product renewal and help the company build durable operating expertise across selected markets.
Multiple Revenue ChannelsThe company combines product sales with service-based pest-management revenue and health-related commercialization. Where recurring service relationships apply, this mix can improve revenue visibility, while broader channels and geographies provide avenues for scaling successful offerings over time.
Meaningful Equity BaseA meaningful equity base and stable asset foundation provide some balance-sheet support despite recent losses and leverage. This does not remove financial risk, but it indicates the company is not thinly capitalized and may retain a broader base for managing operations and pursuing its business activities.
Bears Say
Severe Profitability DeteriorationThe sharp margin contraction and move into operating losses show that recent revenue has not converted efficiently into earnings. Unless profitability improves, weaker earnings can reduce internal funding capacity, constrain reinvestment in products, and make future results more volatile.
Negative Cash GenerationThe reversal from consistently positive operating cash flow through 2024 to negative operating cash flow and substantial free-cash-flow outflow increases funding pressure. Persistently weaker cash conversion would reduce flexibility to invest, absorb setbacks, or support obligations without external financing.
Elevated And Rising LeverageLeverage near the high end of its recent range is more burdensome while profitability and cash generation are weak. Higher debt relative to equity can restrict capital-allocation choices, increase the importance of stable cash inflows, and amplify the effect of further operating deterioration.
CK Life Sciences International (Holdings), Inc. News
0775 FAQ
What was CK Life Sciences International (Holdings), Inc.’s price range in the past 12 months?
CK Life Sciences International (Holdings), Inc. lowest stock price was HK$0.53 and its highest was HK$1.08 in the past 12 months.
What is CK Life Sciences International (Holdings), Inc.’s market cap?
CK Life Sciences International (Holdings), Inc.’s market cap is HK$5.14B.
When is CK Life Sciences International (Holdings), Inc.’s upcoming earnings report date?
CK Life Sciences International (Holdings), Inc.’s upcoming earnings report date is Mar 16, 2027 which is in 166 days.
How were CK Life Sciences International (Holdings), Inc.’s earnings last quarter?
CK Life Sciences International (Holdings), Inc. released its earnings results on Aug 11, 2026. The company reported -HK$0.003 earnings per share for the quarter.
Is CK Life Sciences International (Holdings), Inc. overvalued?
According to Wall Street analysts CK Life Sciences International (Holdings), Inc.’s price is currently Overvalued.
Does CK Life Sciences International (Holdings), Inc. pay dividends?
CK Life Sciences International (Holdings), Inc. pays a Annually dividend of HK$0.008 which represents an annual dividend yield of 1.01%. See more information on CK Life Sciences International (Holdings), Inc. dividends here
What is CK Life Sciences International (Holdings), Inc.’s EPS estimate?
CK Life Sciences International (Holdings), Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CK Life Sciences International (Holdings), Inc. have?
CK Life Sciences International (Holdings), Inc. has 9,611,072,000 shares outstanding.
What happened to CK Life Sciences International (Holdings), Inc.’s price movement after its last earnings report?
CK Life Sciences International (Holdings), Inc. reported an EPS of -HK$0.003 in its last earnings report. Following the earnings report the stock price went down -1.724%.
Which hedge fund is a major shareholder of CK Life Sciences International (Holdings), Inc.?
Currently, no hedge funds are holding shares in HK:0775
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CK Life Sciences International (Holdings), Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-42.47%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
7.78%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
CK Life Sciences International (Holdings), Inc.
CK Life Sciences International (Holdings), Inc. operates as an investment company, which engages in the business of research and development, manufacturing, commercialization, marketing and selling of products and assets in nutraceuticals, pharmaceuticals and agriculture related business. It operates through the following segments: Agriculture-Related and Health. The company was founded on August 10, 2001 and is headquartered in Hong Kong.
CK Life Sciences International (Holdings), Inc. (0775) Earnings & Revenues
Technical Analysis
Sino Biopharmaceutical
―
Ascletis Pharma, Inc.
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Simcere Pharmaceutical Group Limited
―
Shanghai Henlius Biotech, Inc. Class H
―